TScan Therapeutics (TCRX) Current Deferred Revenue (2020 - 2026)
TScan Therapeutics (TCRX) reported Current Deferred Revenue of $586,000 for Q2 2026, down 92.4% from $7.7 million a year earlier and down 64.2% from the prior quarter.
Powered by 
Analysis
TScan Therapeutics (TCRX) Current Deferred Revenue (2020 - 2026) Analysis & Trends
At the end of FY2025, TScan Therapeutics posted Current Deferred Revenue of $2.62 million, down 77.6% from FY2024.
- Current Deferred Revenue has a five-year compound annual growth rate of -24.4% (FY2020 to FY2025).
- By year, Current Deferred Revenue came in at $11.7 million in FY2024 (+15.4%), $10.14 million in FY2023 (+161.7%), $3.87 million in FY2022 (-66.0%) and $11.41 million in FY2021 (+7.4%).
- The Q2 2026 figure ranks as the lowest quarterly Current Deferred Revenue in data going back to Q4 2020.
- Year over year, Current Deferred Revenue has now declined in each of the last six quarters, with an average decline of 43.9% over the last eight quarters.
- The high point for year-over-year Current Deferred Revenue in five years was Q4 2023 (growth of 161.7%); the low point was Q2 2026 (a decline of 92.4%).
- Per Business Quant data, the three quarters before Q2 2026 came in at $1.64 million (Q1 2026), $2.62 million (Q4 2025) and $5.19 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn |
| 10 | TScan Therapeutics | 40.28 Mn | 40.28 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 586,000.00 |
| Mar 31, 2026 | 1.64 Mn |
| Dec 31, 2025 | 2.62 Mn |
| Sep 30, 2025 | 5.19 Mn |
| Jun 30, 2025 | 7.70 Mn |
| Mar 31, 2025 | 10.27 Mn |
| Dec 31, 2024 | 11.70 Mn |
| Sep 30, 2024 | 9.93 Mn |
| Jun 30, 2024 | 10.70 Mn |
| Mar 31, 2024 | 10.44 Mn |
| Dec 31, 2023 | 10.14 Mn |
| Sep 30, 2023 | 15.21 Mn |
| Jun 30, 2023 | 19.21 Mn |
| Dec 31, 2022 | 3.87 Mn |
| Sep 30, 2022 | 5.93 Mn |
| Jun 30, 2022 | 8.17 Mn |
| Mar 31, 2022 | 10.87 Mn |
| Dec 31, 2021 | 11.41 Mn |
| Sep 30, 2021 | 11.97 Mn |
| Jun 30, 2021 | 11.75 Mn |
API Access
TScan Therapeutics Current Deferred Revenue API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=TCRX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "current-deferred-revenue", "ticker": "TCRX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=TCRX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();